Evidence map›Paper›PMID 35463857›Full record

ArticleDiabetology international2022

Production of insulin antibody associated with relapsed hodgkin's lymphoma.

Masatoshi Ikeda, Masaki Fujimura, Kentaro Kurosawa, Shunsuke Tsugawa, Yui Sakuramachi, Kiyoko Takano, Shintaro Okamura, Masako Kitatani, Futoshi Iioka, Satoru Tsujii and 1 more

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetology international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Masatoshi IkedaDepartment of Hematology, Tenri Hospital, 200 Mishima-cho, Tenri, Nara Japan.ORCID 0000-0001-9037-7562
Masaki FujimuraDepartment of Endocrinology, Tenri Hospital, Tenri, Japan.
Kentaro KurosawaDepartment of Endocrinology, Tenri Hospital, Tenri, Japan.
Shunsuke TsugawaDepartment of Endocrinology, Tenri Hospital, Tenri, Japan.
Yui SakuramachiDepartment of Endocrinology, Tenri Hospital, Tenri, Japan.
Kiyoko TakanoDepartment of Endocrinology, Tenri Hospital, Tenri, Japan.
Shintaro OkamuraDepartment of Endocrinology, Tenri Hospital, Tenri, Japan.
Masako KitataniDepartment of Endocrinology, Tenri Hospital, Tenri, Japan.
Futoshi IiokaDepartment of Hematology, Tenri Hospital, 200 Mishima-cho, Tenri, Nara Japan.
Satoru TsujiiDepartment of Endocrinology, Tenri Hospital, Tenri, Japan.
Yasuaki HayashinoDepartment of Endocrinology, Tenri Hospital, Tenri, Japan.
Tenri Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 72-year-old man with type 2 diabetes mellitus with good glucose control for 20 years and maintained on oral hypoglycaemic agents was diagnosed with Hodgkin's Lymphoma (HL) and started on insulin glargine for glycaemic control. Despite increased doses of insulin, his blood glucose levels went up dramatically. The anti-insulin antibody test proved to be positive, and Scatchard plot analysis showed 2 binding sites with relatively low-affinity constants: Supplementary Information: The online version contains supplementary material available at 10.1007/s13340-021-00550-1.

Indexed as

Anti-insulin antibodyBrentuximab vedotinCase reportHodgkin’sLymphomaType 2 diabetes mellitus

Identifiers

PMID35463857
PMCPMC8980128
OpenAlexW3205866069

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.